

**Table S1.** Characteristics of CIN2/3 patients for prognostic evaluation of the GynTest methylation status.

<b>Demographic and baseline standard test data</b>	<b>CIN2 (n=24)</b>	<b>CIN3 (n=36)</b>
Age [years], median (range)	22 (20-29)	22.5 (18-25)
Number of live births, n (%)		
None	23 (96%)	33 (92%)
One	1 (4%)	3 (8%)
Any contraception, n (%)	21 (88%)	27 (75%)
By birth control pill, n/valid* (%)	14/21 (67%)	21/27 (78%)
By condom. n/valid* (%)	4/21 (19%)	4/27 (15%)
Smoker, n (%)		
No	11 (46%)	13 (36%)
Previous	1 (4%)	2 (6%)
Current	11 (46%)	20 (56%)
Unknown	1 (4%)	1 (3%)
<b>Standard tests at baseline, n/valid* (%)</b>		
High risk HPV	23/24 (96%)	29/29 (100%)
HPV16	8/23 (35%)	14/29 (48%)
HPV18	0/23 (0%)	3/29 (10%)
Liquid based cytology (Munich III nomenclature)		
I	0/23 (0%)	1/12 (3%)
II-a	0/23 (0%)	2/29 (7%)
II-p	1/23 (4%)	0/29 (0%)
IIID-1	10/23 (44%)	1/29 (3%)
IIID-2	10/23 (44%)	15/29 (52%)
IVa-p	2/23 (9%)	10/29 (35%)
≤ LSIL	11/23 (48%)	4/29 (14%)
HSIL	12/23 (52%)	25/29 (86%)

\* Valid: Total number of patients without missing data

Abbr.: CIN - Cervical intraepithelial neoplasia; LSIL (HSIL) - Low (High)-grade squamous intraepithelial lesion

**Table S2.** Relationship between GynTect methylation status at baseline (V0) and outcome in patients according to the grading of lesion at study entry (percentages per row may not add up to 100% due to rounding).

Lesion	GynTect methylation status	Outcome			Total
		Regression	Persistence	Progression	
CIN2	Invalide	2 (100%)	0 (0%)	0 (0%)	2
	Negative	12 (67%)	5 (28%)	1 (6%)	18
	Positive	3 (75%)	1 (25%)	0 (0%)	4
	Total	17 (71%)	6 (25%)	1 (4%)	24
CIN3	Invalide	3 (100%)	0 (0%)	0 (0%)	3
	Negative	15 (56%)	12 (44%)	0 (0%)	27
	Positive	2 (33%)	4 (67%)	0 (0%)	6
	Total	20 (56%)	16 (44%)	0 (0%)	36
CIN2/3	Invalide	5 (100%)	0 (0%)	0 (0%)	5
	Negative	27 (60%)	17 (38%)	1 (2%)	45
	Positive	5 (50%)	5 (50%)	0 (0%)	10
	Total	37 (62%)	22 (37%)	1 (2%)	60

**Table S3.** Relationship between cytology classified as low (LSIL)- and high (HSIL)- grade squamous intraepithelial lesion and methylation status at baseline (V0) in CIN2/3 patients with valid data for both diagnostic tests (Fisher's exact test: p=0.41).

Cytology	GynTect methylation status		
	Negative	Positive	Total
≤ LSIL	12 (92%)	1 (8%)	13 (100%)
HSIL	27 (77%)	8 (23%)	35 (100%)
Total	39 (81%)	9 (19%)	48 (100%)

**Table S4.** Relationship between high-risk HPV types and methylation status at baseline (V0) in CIN2/3 patients with valid data for both diagnostic tests (Fisher's exact test:  $p < 0.01$ ).

High risk HPV	GynTect methylation status		
	Negative	Positive	Total
Other high-risk types	24 (96%)	1 (4%)	25 (100%)
HPV16 or 18	15 (65%)	8 (35%)	23 (100%)
Total	39 (81%)	9 (19%)	48 (100%)